Continuing episodes of pain in recurrent acute pancreatitis: Prospective follow up on a standardised protocol with drugs and pancreatic endotherapy

Table 4 Comparison of serum C peptide and faecal elastase levels at baseline and end of follow up

	Baseline	1 yr	P value
All patients (n = 39)
C Peptide (35)	3.2 (2.8, 4.3)	6.4 (2.6, 11.5)	0.001
F Elastase (38)	401.94 (215.5, 484.8)	559.6 (411.3, 597.4)	< 0.001
Patients on DT (n = 21)
C Peptide (21)	4.13 (3.11, 4.35)	4.47 (2.55, 11.65)	0.079
F Elastase (24)	406.18 (220, 496.43)	559.55 (442.24, 597.30)	0.002
Patients on ET (n = 14)
C Peptide (14)	2.85 (2.15, 3.53)	7.52 (2.33,10.35)	0.004
F Elastase (14)	335.87 (207.3, 481.41)	562.70 (265.47, 597.35)	0.006

Data expressed as median (quartiles). DT: Drug therapy; ET: Endoscopic therapy.